LLY

1,009.78

+2.29%↑

JNJ

230.21

+1.07%↑

ABBV

213.46

+1.18%↑

UNH

393.26

+1.95%↑

AZN

185.37

+0.94%↑

LLY

1,009.78

+2.29%↑

JNJ

230.21

+1.07%↑

ABBV

213.46

+1.18%↑

UNH

393.26

+1.95%↑

AZN

185.37

+0.94%↑

LLY

1,009.78

+2.29%↑

JNJ

230.21

+1.07%↑

ABBV

213.46

+1.18%↑

UNH

393.26

+1.95%↑

AZN

185.37

+0.94%↑

LLY

1,009.78

+2.29%↑

JNJ

230.21

+1.07%↑

ABBV

213.46

+1.18%↑

UNH

393.26

+1.95%↑

AZN

185.37

+0.94%↑

LLY

1,009.78

+2.29%↑

JNJ

230.21

+1.07%↑

ABBV

213.46

+1.18%↑

UNH

393.26

+1.95%↑

AZN

185.37

+0.94%↑

Home・Elenco Azioni・Heron Therapeutics Inc

Heron Therapeutics Inc

Aperta

SettoreSettore sanitario

0.86 -1.15

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.84

Massimo

0.88

Metriche Chiave
By Trading Economics
Entrata	-5.2M -8.1M
Vendite	-5.9M 35M
EPS	-0.04
Margine di Profitto	-23.367
Dipendenti	128
EBITDA	-4M -4.8M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+311.76% upside

Dividendi
By Dow Jones
Utili prossimi	7 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-49M 181M
Apertura precedente	2.01
Chiusura precedente	0.86

Notizie sul Sentiment di mercato

By Acuity

67%

33%

298 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

2.0001 / 2.42 Supporto e resistenza

Heron Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 mag 2026, 23:10 UTC

Azioni calde

Stocks to Watch: Agilysys, XP

18 mag 2026, 18:44 UTC

I principali Market Mover

Claritev Shares Recover After Comments About DOJ

18 mag 2026, 23:55 UTC

Utili

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 mag 2026, 23:47 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

18 mag 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 mag 2026, 23:37 UTC

Discorsi di Mercato

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 mag 2026, 22:31 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 mag 2026, 22:30 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 mag 2026, 22:30 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 mag 2026, 22:25 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 mag 2026, 22:24 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

18 mag 2026, 20:50 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

18 mag 2026, 20:25 UTC

Utili

Correct: XP 1Q Total Client Assets BRL1.53T

18 mag 2026, 20:23 UTC

Utili

XP 1Q Total Client Assets BRL1.53B

18 mag 2026, 20:19 UTC

Utili

XP 1Q Adj EPS BRL2.49 >XP

18 mag 2026, 20:19 UTC

Utili

XP 1Q Rev BRL4.73B >XP

18 mag 2026, 19:10 UTC

Discorsi di Mercato

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 mag 2026, 19:00 UTC

Utili

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 mag 2026, 18:52 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 mag 2026, 18:17 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 mag 2026, 17:22 UTC

Discorsi di Mercato

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 mag 2026, 16:57 UTC

Acquisizioni, Fusioni, Takeovers

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 mag 2026, 16:57 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

18 mag 2026, 16:57 UTC

Discorsi di Mercato

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 mag 2026, 16:54 UTC

Acquisizioni, Fusioni, Takeovers

Vinci Doesn't Set Out Financial Details of Deal

18 mag 2026, 16:50 UTC

Acquisizioni, Fusioni, Takeovers

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 mag 2026, 16:49 UTC

Acquisizioni, Fusioni, Takeovers

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 mag 2026, 16:49 UTC

Acquisizioni, Fusioni, Takeovers

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 mag 2026, 16:48 UTC

Acquisizioni, Fusioni, Takeovers

Vinci Buys Canada's Modern Group of Companies

Confronto tra pari

Modifica del prezzo

Heron Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

311.76% in crescita

Previsioni per 12 mesi

Media 3.5 USD 311.76%

Alto 4 USD

Basso 3 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Heron Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 2 che hanno fornito valutazioni azionarie a Heron Therapeutics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

2.0001 / 2.42Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

298 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.